Michael J. Dowzicky

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)

Daryl J. Hoban, Samuel K. Bouchillon, Brian Johnson et al. · Diagnostic Microbiology and Infectious Disease · 2005 · 205 citations

Pharmacology, Surveillance Trial, Global Tigecycline Evaluation +1

Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline

R. R. Reinert, Donald E. Low, F. Rossi et al. · Journal of Antimicrobial Chemotherapy · 2007 · 188 citations · Full text

Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial

Anna Giammanco, Cinzia Calà, Teresa Fasciana et al. · mSphere · 2017 · 168 citations · Full text

Determining incidence of extended spectrum β-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001–2002

S. Bouchillon, Brian Johnson, D. Hoban et al. · International Journal of Antimicrobial Agents · 2004 · 141 citations

Vancomycin-resistant Enterococcus Faecium, Extended Spectrum, Antibiotic Resistance +16

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit

Hélio S. Sader, Ronald N. Jones, Michael J. Dowzicky et al. · Diagnostic Microbiology and Infectious Disease · 2005 · 113 citations

Nosocomial Bacterial Pathogens, Antimicrobial Susceptibility, Intensive Care Unit +8